Today's Post-Market Laggard: Tekmira Pharmaceuticals (TKMR)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Tekmira Pharmaceuticals ( TKMR) as a post-market laggard candidate. In addition to specific proprietary factors, Trade-Ideas identified Tekmira Pharmaceuticals as such a stock due to the following factors:

  • TKMR has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $61.2 million.
  • TKMR is down 2.2% today from today's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in TKMR with the Ticky from Trade-Ideas. See the FREE profile for TKMR NOW at Trade-Ideas

More details on TKMR:

Tekmira Pharmaceuticals Corporation, a biopharmaceutical company, focuses on the research and development of RNA interference therapeutics; and provides lipid nanoparticle delivery technology to pharmaceutical partners in Canada. Currently there are 6 analysts that rate Tekmira Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Tekmira Pharmaceuticals has been 2.8 million shares per day over the past 30 days. Tekmira has a market cap of $425.1 million and is part of the health care sector and drugs industry. Shares are up 136.8% year-to-date as of the close of trading on Thursday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreetRatings.com Analysis:

TheStreet Quant Ratings rates Tekmira Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income.

If you liked this article you might like

3 Stocks Pushing The Drugs Industry Lower

Tekmira Pharmaceuticals (TKMR) Weak On High Volume

Tekmira Pharmaceuticals (TKMR): Today's Weak On High Volume Stock

'Mad Money' Lightning Round: Buy, Buy, Buy Yahoo!, Not Alibaba

Jim Cramer's 'Mad Money' Recap: 'Hit and Run' Investors Are the Worst